Printer Friendly

Zynerba initiates Phase 2 BRIGHT trial.

Zynerba announced that it has initiated the Phase 2 BRIGHT trial. The trial will assess the safety, tolerability and efficacy of Zygel for the treatment of child and adolescent patients with Autism Spectrum Disorder, or ASD. The company expects to present topline data from this study in the first half of 2020. The 14-week BRIGHT trial is an open-label multi-dose Phase 2 clinical trial designed to evaluate the efficacy and safety of Zygel in approximately 36 children and adolescents with ASD as confirmed by DSM-5 diagnostic criteria for ASD. Enrolled patients will receive weight-based initial doses of 250 mg daily or 500 mg daily of Zygel.

COPYRIGHT 2019 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Mar 7, 2019
Previous Article:Entera Bio CFO Mira Rosenzweig to leave company in April.
Next Article:Pivotal Research downgrades United Natural Foods to Sell, cuts target to $8.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters